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Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic
leukemia (B-ALL) displays a poor prognosis in about 15–20% of pediatric cases and
about 60% of adult patients. In addition, life-long irreversible late effects from chemo-
and radiation therapy, including secondary malignancies, are a growing problem for
leukemia survivors. Targeted therapy holds promising perspectives for cancer
treatment as it may be more effective and have fewer side effects than conventional
therapies. The phosphatidylinositol 3-phosphate kinase (PI3K)/Akt/mechanistic target
of rapamycin (mTOR) signaling pathway is a key regulatory cascade which controls
proliferation, survival and drug-resistance of cancer cells, and it is frequently
upregulated in the different subtypes of B-ALL, where it plays important roles in
the pathophysiology, maintenance and progression of the disease. Moreover,
activation of this signaling cascade portends a poorer prognosis in both pediatric
and adult B-ALL patients. Promising preclinical data on PI3K/Akt/mTOR inhibitors
have documented their anticancer activity in B-ALL and some of these novel drugs
have entered clinical trials as they could lead to a longer event-free survival and reduce
therapy-associated toxicity for patients with B-ALL. This review highlights the current
status of PI3K/Akt/mTOR inhibitors in B-ALL, with an emphasis on emerging evidence
of the superior efficacy of synergistic combinations involving the use of traditional
chemotherapeutics or other novel, targeted agents.
K E YWORD S
B-ALL, combination therapy, PI3K/Akt/mTOR signaling, protein kinase inhibitors, targeted
therapy
1 | INTRODUCTION
B-lineage acute lymphoblastic leukemia (B-ALL) is a hematological
malignancy characterized by the uncontrolled proliferation of B-cell
precursors. B-ALL displays a bimodal distribution with approximately
60% of cases occurring in patients younger than 20 years of age and
accounting for roughly 80% of pediatric leukemias (Pui, Relling, &
Downing, 2004). The second peak occurs around the fifth decade
of life, however it accounts for only 20% of leukemias diagnosed in
adult patients. At present, 95% of pediatric B-ALL patients reach a
complete remission (CR), while the estimated 5-year survival ratesCarolina Simioni and Alberto M. Martelli equally contributed to this article.
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(EFS) are 85–90% (Pui et al., 2004; Pui et al., 2014). As to adults, they
have CR rates of about 85%, however their 5-year survival rate is 40%
overall and approximately 7% for patients who experience relapse
(Fielding et al., 2007; Goldstone et al., 2008). Indeed, adults are at a
higher risk of relapse due to disease factors present at diagnosis,
including the Philadelphia chromosome (Ph) formed upon the t(9;22)
reciprocal translocation that fuses the breakpoint cluster region (Bcr)
gene with the Abelson tyrosine kinase (Abl) (Lafage-Pochitaloff et al.,
2017). The incidence of Ph+ B-ALL increases with age and occurs in up
to 50% of B-ALL diagnosed in individuals ≥50 year old (Pui & Evans,
2006). Depending on the translocation breakpoint in Bcr, different
Bcr-Abl isoforms are expressed, which all contain exons 2–11 of the
Abl gene, but different lengths of their Bcr component (Deininger,
Goldman, & Melo, 2000). The most common Bcr-Abl isoforms are
p190 (alternatively named: p185) and p210.While p210 is the hallmark
of chronic myelogenous leukemia, p190 occurs in the majority of Ph+
B-ALL. It is intriguing that, very recently, marked differences in the
interactome and tyrosine phosphoproteome of p190 and p210
Bcr-Abl isoforms were found (Cutler et al., 2017; Reckel et al.,
2017). Besides other aspects, these findings could give important
indications regarding differential sensitivity to kinase inhibitors and
other targeted agents.
Philadelphia chromosome-like B-ALL (Ph-like B-ALL) is a recently
identified high-risk B-ALL subtype. It occurs more frequently in
adolescent and adult patients, having been reported in as many as 27%
of young adults with B-ALL between 21 and 39 years of age, while only
10% of childhood B-ALL cases are Ph-like (Tran & Loh, 2016). This
aggressive B-ALL subtype is characterized by a gene expression profile
similar to that of Ph+ B-ALL, however the Bcr-Abl fusion protein is not
expressed. Nevertheless, Ph-like B-ALL cells harbor a multitude of
genetic alterations that activate several cytokine receptor genes and
kinase signaling pathways resulting in a consequent poor prognosis
(Ofran & Izraeli, 2017).
Although in childhood B-ALL patients multiagent chemotherapy
has had a great success, the same is not true in adults, even with the
introduction of tyrosine kinase inhibitors (TKIs) targeting Bcr-Abl
kinase, in combination with chemotherapy (Malagola, Papayannidis, &
Baccarani, 2016).
Moreover, in refractory or relapsed settings, the outcome of
pediatric B-ALL is still poor (Pui & Evans, 2006). Furthermore, the long-
term adverse effects of polychemotherapy and radiotherapy increase
the risk of morbidity and premature death, especially in children (Ness,
Armenian, Kadan-Lottick, & Gurney, 2011). Therefore, the identifica-
tion of novel targeted therapies for supporting conventional
chemotherapy is urgently needed to further improve the outcome
of B-ALL in both adult and pediatric patients (Dias, Kenderian, Westin,
& Litzow, 2016).
A promising candidate for the development of targeted
therapies is the phosphatidylinositol kinase (PI3K)/Akt/mechanistic
target of rapamycin (mTOR) pathway. This signaling cascade is
involved in a wide array of physiological processes whose
deregulation is frequently associated with tumorigenesis, including
mRNA translation, apoptosis, autophagy, metabolism, migration, and
angiogenesis (Pons-Tostivint, Thibault, & Guillermet-Guibert, 2017;
Bahrami et al., 2018).
Overall, this pathway is one of the most frequently mutated and
aberrantly activated networks in different types of cancers (Guerrero-
Zotano, Mayer, & Arteaga, 2016), including acute leukemias (Bertacchini
et al., 2015). For this reason, pharmaceutical companies have developed
many selective inhibitors of the key effectors of this complex signaling
cascade (Rodon&Tabernero,2017).However, a growingbodyofevidence
indicates that small molecules targeting PI3K/Akt/mTOR signaling are
most effective against cancer cells when used in combination with other
therapeutic agents.
Aberrant activity of the PI3K/Akt/mTOR network is commonly
detected in adult B-ALL (Gomes et al., 2014), while pathway activation
is associated with poor prognosis and chemoresistance in pediatric B-
ALL cases (Morishita et al., 2012; Nemes et al., 2013), and high
expression of mTOR has been very recently demonstrated to correlate
with a poor clinical outcome in both adult and childhood B-ALL
(Khanna et al., 2017). Moreover, glycogen synthase kinase-3β (GSK-
3β), an Akt downstream target (Hermida, Dinesh Kumar, & Leslie,
2017), is a negative prognostic indicator in acute leukemias, including
childhood B-ALL (Ruvolo, 2017; Tovar, Zeron, Romero, Sanchez, &
Romero, 2016). These findings have provided a rationale for exploring
the efficacy in the clinic of small molecules targeting this pathway in
association with chemotherapy in B-ALL patients (Daver et al., 2015).
In this article, following a brief overview of what is known about
PI3K/Akt/mTOR signaling in general and in B-ALL in particular, we will
summarize the recent advances on its relevance as a potential
therapeutic target in the various subtypes of B-ALL, with a particular
emphasis on the combinatorial use of PI3K/Akt/mTOR inhibitors as
novel therapeutic strategies.
2 | PI3K/Akt/mTOR SIGNALING
The PI3K family comprises lipid kinases that phosphorylate the 3′-OH
of the inositol ring. PI3K isoforms are grouped into three classes,
displaying distinct substrate specificity, and lipid products (Cantley,
2002). For the scopes of this review, we will mainly focus on class I
PI3Ks as they are the best understood and the most widely implicated
in human malignancies (Engelman, Luo, & Cantley, 2006; Millis, Ikeda,
Reddy, Gatalica, & Kurzrock, 2016). Class I PI3Ks phosphorylate
phosphatidylinositol-4,5-bisphosphate (PIP2) to yield phosphatidyli-
nositol-3,4,5-trisphosphate (PIP3). Class I PI3Ks are divided into two
subgroups: A and B. Class IA PI3Ks contain one of three catalytic
subunits (p110α, p110β, p110δ) that form heterodimers with one of
the five adaptor/regulatory isoforms (p85α, p85β, p55α, p55γ, p50α).
Class IA PI3Ks are activated downstream of either tyrosine kinase
receptors (TKRs) or G protein-coupled receptors (GPCRs). The single
class IB PI3K comprises the p110γ catalytic subunit which binds one of
two related regulatory subunits, either p101 or p87. Class IB PI3Ks
mainly act downstream of GPCRs, however they can be stimulated by
TKRs (Franke, 2008; Vanhaesebroeck, Guillermet-Guibert, Graupera,
& Bilanges, 2010). Upon activation by growth factors, hormones, and
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cytokines, class I PI3Ks initiate a cascade of events that promote
cancer cell proliferation, survival, migration, drug-resistance, and
glycolytic metabolism.
Class II PI3Ks can be activated by TKRs, cytokine receptors and
integrins, however their specific functions in cancer are still not well
understood (Falasca et al., 2017).
Class III PI3K comprises only a heterodimeric enzyme consisting of
a catalytic (Vps34) and an adaptor (p150) subunit (Yu, Long, & Shen,
2015). Vps34 is implicated in the regulation of autophagy in response
to cellular stresses.
Akt is a serine/threonine kinase belonging to the AGC protein
kinase family. Akt is a critical effector of PI3K in carcinogenesis, as
documented by the fact that about 400 proteins contain the
consensus sequence for Akt phosphorylation. The heterogeneity of
proteins potentially phosphorylated by Akt supports the its key role
in cell cycle progression, survival, mRNA translation, glycolysis, and
angiogenesis (Manning & Toker, 2017; Martini, De Santis, Braccini,
Gulluni, & Hirsch, 2014).
The recruitment of inactive Akt from the cytosol to the plasma
membrane requires that the pleckstrin homology (PH) domain of Akt
binds to PIP3 synthesized by PI3K. Akt is then phosphorylated at Thr
308 by phosphatidylinositol-dependent kinase 1 (PDK1) and at Ser
473 by mTOR complex 2 (mTORC2), resulting in full activation of Akt
activity (Georgescu, 2010).
mTOR is a serine/threonine kinase which belongs to the PI3K-
related kinase (PIKK) family (Memmott & Dennis, 2009; Shen et al.,
2018). mTOR is the catalytic subunit of two distinct multiprotein
complexes, referred to as mTOR complex 1 (mTORC1) and mTORC2,
which display different sensitivity to rapamycin and differ in their
protein composition.
mTORC1 is characterized by the interactions between mTOR
and the regulatory associated protein of mTOR (Raptor) which
regulates mTOR activity and functions as a scaffold for recruiting
mTORC1 substrates. This complex also comprises DEP-domain-
containing mTOR interacting protein (Deptor), prolin-rich Akt
substrate 40-kDa (PRAS40), mammalian lethal with Sec13 protein
8 (mLST8), and Tti1/Tel2.
mTORC1 is sensitive to rapamycin and its analogs (rapalogs) that
are allosteric mTORC1 inhibitors and do not target the mTOR catalytic
site (Alayev & Holz, 2013; Kim et al., 2002; Oshiro et al., 2004).
mTORC1 controls translation in response to growth factors/nutrients
through the phosphorylation of p70S6 kinase (p70S6K) and 4E-BP1
(Browne & Proud, 2004; Ma & Blenis, 2009; Shahbazian et al., 2010).
Importantly, mTORC1 represses autophagy, a lysosome-dependent
degradation pathway which allows cells to recycle damaged or
superfluous cytoplasmic content (Chen et al., 2010; Fu et al., 2017,
2018). As a consequence, cells produce metabolic precursors for
macromolecular biosynthesis or ATP generation. In cancer cells,
autophagy fulfills a dual role, because it can display both tumor-
suppressing and tumor-promoting functions. Indeed, the autophagic
machinery prevents necrosis and inflammation, that can lead to
genetic instability and tumorigenesis (Galluzzi, Bravo-San Pedro,
Levine, Green, & Kroemer, 2017; Sugiyama et al., 2017; Wang, Zhang,
Luo, Ning, & Fang, 2018). However, autophagy may be important for
cancer progression, by providing energy through its recycling
mechanism during unfavorable metabolic circumstances, that are
very common encountered by tumor cells (Janku, McConkey, Hong, &
Kurzrock, 2011; Won et al., 2018).
mTORC2 comprises the rapamycin-insensitive companion of
mTOR (Rictor), Deptor, protein observed with rictor-1 (Protor-1),
mLST8, mammalian stress-activated protein kinase interacting protein
(mSIN1), and Tti1/Tel2. mTORC2 is generally described as being
insensitive to rapamycin/rapalogs. However, long-term (>24 hr)
treatment of cancer cells with rapamycin/rapalogs could result in
mTORC2 activity inhibition (Dunlop & Tee, 2009; Rosner &
Hengstschlager, 2008).
mTORC1 activity is quite well understood and is mainly regulated
thorugh PI3K/Akt signaling (Ilagan & Manning, 2016), although MEK/
ERK could be also involved (Zeng et al., 2018).
In contrast, the mechanisms that control mTORC2 have only
begun to be revealed (Sparks & Guertin, 2010), however mTORC2
activation by growth factors requires PI3K, as pharmacological
inhibition of PI3K decreased mTORC2 activity in vitro (Huang, Dibble,
Matsuzaki, & Manning, 2008; Liu et al., 2015).
PI3K, Akt, and mTORC1/2 are linked to each other via regulatory
feedback loops that restrain their simultaneous hyperactivation
(Dunlop & Tee, 2009). A negative regulation of Akt activity by
mTORC1 is dependent on p70S6K-mediated phosphorylation of
insulin receptor substrate (IRS) −1 and −2 adaptor proteins,
downstream of the insulin receptor (IR) or insulin-like growth factor-
1 receptor (IGF-1R) (Bhaskar and Hay, 2007; Lang et al., 2010; Shah,
Wang, & Hunter, 2004). IRS-1 and IRS-2 are normally required to
activate class IA PI3Ks after stimulation of IR/IGF-1R tyrosine kinase
activity.WhenmTORC1 is active, p70S6K phosphorylates IRS-1/-2 on
Ser residues, targeting them for proteasomal degradation (Sriburi,
Jackowski,Mori, & Brewer, 2004; Xu et al., 2008). Therefore, mTORC1
signaling inhibition by rapamycin/rapalogs blocks this negative
feedback loop and hyperactivates Akt through PI3K and PDK1 (Alayev
et al., 2017; Bertacchini et al., 2014).
PI3K/Akt/mTOR network function is mainly controlled by inositol
lipid phosphatases (Rodgers, Ferguson, Mitchell, & Ooms, 2017). In
particular, phosphatase and tensin homolog deleted on chromosome
10 (PTEN) is a major negative regulator of the newtwork as it removes
the 3′-phosphate from PIP3, thereby antagonizing PI3K signaling (Xie,
Naizabekov, Chen, & Tokay, 2016).
3 | THE PI3K/Akt/mTOR PATHWAY IN
B-ALL
Activation of PI3K/Akt/mTOR signaling is a common event in B-ALL
cell lines and patient samples.
In Ph+ leukemic cells, PI3K activation is dependent on the
presence of a multiprotein complex that, besides p110 and p85 PI3K,
comprises Bcr-Abl, its substrate c-CBL (i.e., the cellular homolog of the
v-Cbl oncoprotein [Brehme et al., 2009]), and the adaptor proteins,
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CRKL and c-CRK (Gotoh, Miyazawa, Ohyashiki, & Toyama, 1994;
Sattler et al., 1996; Skorski et al., 1995). The leukemogenic potential of
activated PI3K is supported by the evidence that deletion of both
Pik3r1 and Pik3r2 (which encode for class IA PI3K p85α and p85β,
respectively [Vanhaesebroeck, Vogt, & Rommel, 2010]) markedly
impaired leukemic transformation in a murine model of Ph+ B-ALL
(Kharas et al., 2004, 2008). Othermodels of activation of PI3K in Ph+ B-
ALL have been proposed, including Src family kinases, Ras, and IRS-1
(Kharas & Fruman, 2005).
Downregulation of PTEN gene expression has been observed in a
Bcr-Abl-expressing murine pre-B-cell line, whereas PTEN overexpres-
sion delayed Ph+ B-ALL development in mice (Peng et al., 2010).
Nevertheless, these results could not be confirmed using primary
samples from adult patients with Ph+ B-ALL. However, in human Ph+
B-ALL PTEN, although expressed, is functionally inactivated (see
further on). Themechanisms of PI3K/Akt/mTOR signaling activation in
Ph+ B-ALL are highlighted in Figure 1a.
Regarding Ph− B-ALL, evidence suggests that upregulation of
the PI3K/Akt/mTOR network could be dependent on constitutively
active pre-B-cell receptor (pre-BCR) signaling that characterizes
approximately 13% of Ph− B-ALL cases, whereas most Ph- B-ALL
cases lack expression of functional pre-BCR (Eswaran et al., 2015;
Geng et al., 2015). However, it is unclear how active pre-BCR could
positively impact on PI3K/Akt/mTOR activity. Given that pre-BCR+
B-ALL patients exhibit significantly higher expression and activity of
Src family kinases, it might be that upregulation of the PI3K/Akt/
mTOR cascade involves Syk, Fyn, or Lyn kinases (Geng et al., 2015;
Kohrer et al., 2016). Moreover, expression and activity of PTEN were
low in pre-BCR+ B-ALL cells (Geng et al., 2015).
Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) are essential for
normal lymphocyte development and homeostasis, whereas aber-
rant IL-7/IL7R-mediated signaling promotes leukemogenesis (Oli-
veira et al., 2017). Interestingly, in Ph− B-ALL gain-of-function
mutations in IL-7Rα were associated with the aberrant expression of
cytokine receptor-like factor 2 (CRLF2). Mutant IL-7Rα formed a
functional receptor with CRLF2 for thymic stromal lymphopoietin
(TSLP), which is closely related to IL-7 (Shochat et al., 2011, 2014).
Although no evidence was provided that these mutations would
FIGURE 1 Mechanisms of PI3K/Akt/mTOR signaling activation in B-ALL subtypes. (a) Ph+ B-ALL. In this subtype, the Bcr-Abl substrate,
c-CBL, forms a multimeric complex consisting of Bcr-Abl itself, both p85 and p110 PI3K, as well as the adaptor proteins, CRKL and
c-CRK. The complex increases PIP3 production from PIP2 through PI3K activity (Sattler et al., 1996). In a murine model of Ph+ B-ALL, it
has also been reported that Bcr-Abl downregulated PTEN gene expression, which resulted in increased levels of PIP3 (Peng et al., 2010).
However, this mechanism of activation has not been confirmed using primary human Ph+ B-ALL samples, where PTEN protein was
upregulated but functionally inhibited (Gomes et al., 2014). (b) Ph− B-ALL. In this subset of B-ALL, the aberrant upregulation of the
PI3K/Akt/mTOR network could be due to TSLP/mutated IL-7Rα/CRLF2 signaling (Shochat et al., 2011, 2014), ETV6/RUNX1 fusion gene
(Fuka et al., 2012), disregulated pre-BCR signaling through Fyn, Lyn, or Syk kinases (Geng et al., 2015; Kohrer et al., 2016), or increased
CK2 activity ensuing in PTEN phosphorylation and inhibition of its lipid phosphatase activity on PIP3 (Gomes et al., 2014). (c) Ph-like
B-ALL. Here, multiple genetic aberrations of LNK/SH2B3, CLRF2, JAK 1/2, IL-7Rα, Abl 1/2, PDGFRB, CSF1R, and EPOR have the
potential for activating PI3K/Akt/mTOR signals (Tasian et al., 2017)
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result in PI3K/Akt/mTOR signaling activation, it is worth highlighting
here that findings from other groups documented how TSLP
promoted B-ALL cell survival and proliferation through the
upregulation of the PI3K/Akt/mTOR network (Brown et al., 2007;
Tasian et al., 2012). It is therefore plausible that IL-7Rα mutations
could be one of the determinants of aberrant activation of the PI3K/
Akt/mTOR cascade in Ph− B-ALL.
The ETV6/RUNX1 fusion gene is present in approximately 25%
of childhood B-ALL patients and represents the molecular equivalent
of the t(12;21) translocation (Romana et al., 1995). Down-regulation
of the endogenous ETV6/RUNX1 fusion protein with shRNA in
B-ALL cell lines resulted in suppression of cytokine-mediated
PI3K/Akt/mTOR signaling. However, no mechanistic explanation
of how ETV6/RUNX1 protein could impact on PI3K/Akt/mTOR
cascade was provided by the authors (Fuka et al., 2012).
As to PTEN, it has been demonstrated that adult Ph− and Ph+ both
B-ALL primary samples displayed decreased PTEN activity and
constitutive hyperactivation of PI3K/Akt/mTOR pathway despite
high PTEN protein levels (Gomes et al., 2014). PTEN functional
inactivation was dependent on CK2 that targets several Ser/Thr
residues located at the C-terminal tail of PTEN (Buontempo et al.,
2018). Indeed, treatment of B-ALL primary cells and cell lines with the
CK2 inhibitor CX-4945 resulted in decreased PTEN phosphorylation,
downregulation of PTEN protein expression, increased PTEN lipid
phosphatase activity, and Akt dephosphorylation. These results
indicated that CK2 activity could be responsible for PTEN post-
translational inactivation and upregulation of the PI3K/Akt/mTOR
network in B-ALL cells (Gomes et al., 2014).
Overall, these findings have documented that multiple mecha-
nisms could be involved in activation of PI3K/Akt/mTOR signaling in
Ph− B-ALL (Figure 1b).
As to Ph-like B-ALL, aberrant PI3K/Akt/mTOR signaling has
been reported in this disease subset which frequently displays a
wide array of genetic anomalies which result in upregulation of
signaling pathways downstream of LNK/SH2B3, CLRF2, JAK 1/2,
IL-7Rα, Abl 1/2, platelet-derived growth factor receptor-β
(PDGFRB), colony-stimulating factor-1 receptor (CSF1R), and
erythropoietin receptor (EPOR) (Cheng et al., 2016; Reshmi et al.,
2017). All of these aberrations have the potential for driving PI3K/
Akt/mTOR signaling (Maude et al., 2012; Tasian et al., 2017; Vo
et al., 2017) (Figure 1c).
4 | THERAPEUTIC TARGETING OF
PI3K/Akt/mTOR IN PRECLINICAL
MODELS OF B-ALL
Many small molecules targeting different nodes of the PI3K/Akt/
mTOR signaling cascades have been or are in clinical development,
however it is still unclearwhich of the different drugs could provide the
greatest therapeutic index (Rodon & Tabernero, 2017). We will now
review the different classes of inhibitors which have been tested in
preclinical models of B-ALL subtypes (Table 1 and Figure 2).
5 | PI3K INHIBITORS
PI3K inhibitors comprise pan p110 PI3K inhibitors and isoform-
specific inhibitors. The first report showing that a pan p110 PI3K
inhibitor (LY294002) could induce either cell cycle arrest or
apoptosis in a Ph- B-ALL cell line, RS4;t11, dates back to 2004
when it was observed that Akt activation was required for the
protective effects exerted by human stromal cells on B-ALL cells
exposed to chemotherapeutic drugs such as Ara-C and etoposide
(Wang, Fortney, & Gibson, 2004). These results were confirmed by
another group which demonstrated, using BLIN-2 B-ALL cells, that
either LY294002 or rapamycin, were proapoptotic only when
combined with U0126, a MEK inhibitor. In contrast, when these
drugs were combined with a JAK2 inhibitor (AG490) they were
cytostatic, as they blocked cell proliferation, even when leukemic
cells were co-cultured with stromal cells (Bertrand, Spengemen,
Shelton, & McCubrey, 2005). However, LY294002 has not been
clinically developed, mainly due to solubility problems.
The clinical grade pan p110 PI3K inhibitor BKM-120 (Buparlisib)
has been tested in long-term cultures of primary Ph+ and Ph− B-ALL
cells (Badura et al., 2013). BKM-120 induced both cell cycle arrest and
apoptosis. Nevertheless, its antiproliferative effects were more
evident in Ph− cells when compared to Ph+ cells, whereas apoptosis
induction was stronger in Ph+ samples. More recently, the proapop-
totic activity of BKM-120 in Ph− NALM-6 B-ALL cells was linked to
upregulation of p53-regulated genes (Bashash et al., 2016).
Selective inhibitors, targeting one or two of the p110 PI3K
catalytic subunits, have been synthesized with the hope that they
would result in lower systemic toxicities than pan p110PI3K inhibitors
(Hirsch & Chiarle, 2012). In consideration of the high levels of
expression of p110δ PI3K in healthy lymphocytes (Chiu et al., 2017),
inhibitors selectivity targeting this p110 PI3K isoform have been
tested in preclinical models of Ph- B-ALL. CAL-101 (Idelalisib) is a
p110δ PI3K inhibitor whose use has been approved by the U.S. Food
and Drug Administration (FDA) in combination with rituximab, an anti-
CD20 antibody, as a second-line treatment for relapsed chronic
lymphocytic leukemia (CLL) patients (Jones et al., 2017).
CAL-101 exerted cytotoxic effects against Nalm-6 B-ALL cells
mediated by G1 blockage (presumably as a result of upregulated p21)
and induction of caspase-dependent apoptosis, likely through reactive
oxygen species-dependent upregulation of FOXO3a and subsequent
induction of the proapoptotic target genes of p53 (Safaroghli-Azar,
Bashash, Sadreazami, Momeny, & Ghaffari, 2017). Furthermore, CAL-
101 increased the cytotoxicity of either doxorubicin (Safaroghli-Azar
et al., 2017) or vincristine (Adam et al., 2017). Importantly, CAL-101
was able to decrease Akt phosphorylation at Ser 473 which was
increased when B-ALL cell lines were co-cultured with OP-9 stromal
cells (Adam et al., 2017). Furthermore, CAL-101 inhibited B-ALL cell
migration to CXCL-12 (SDF-1α) in vitro and blocked homing of B-ALL
cells to the bone marrow in vivo. It was thus concluded that inhibition
of homing of circulating B-ALL cells to the bone marrow or even
mobilization of leukemic cells from their protective niches in the bone
marrow might interfere with cell adhesion-mediated drug-resistance
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(Adam et al., 2017). Overall, these findings support the rationale for
clinical testing of p110δ PI3K inhibitors in B-ALL and provide useful
insights needed to optimize the therapeutic strategy.
Glucocorticoids (GCs) are widely used in chemotherapeutic
protocols for B-ALL, due to their strong proapoptotic activity to
leukemic cells. It was recently disclosed that dexamethasone (DEX)
partially suppresses the PI3K/Akt signaling cascade in B-ALL cells. This
results in nuclear translocation of the Akt substrate FOXO3a, which
induces the expression of downstream targets, including p27Kip1 and
Bim (Consolaro et al., 2015). We have recently studied the therapeutic
potential of a panel of pan and isoform-selective p110 PI3K inhibitors,
used alone or combined with DEX, in B-ALL leukemia cell lines and
primary pediatric samples. We found that ZSTK-474, a pan p110 PI3K
inhibitor, displayed the most powerful cytotoxic effects in B-ALL cells.
However, both ZSTK-474 and the dual γ/δ p110PI3K inhibitor IPI-145
(Duvelisib), sensitized B-ALL cells to DEX by restoring nuclear
TABLE 1 PI3K/AKT/mTOR inhibitors used alone or in combination in preclinical models of B-ALL
Inhibitor Target Synergysm with B-ALL subtype References
LY294002 Class IA PI3Ks Cytarabine, Etoposide,
U0126, AG490
Ph− B-ALL Bertrand et al. (2005);
Wang et al. (2004)
BKM-120 Class IA PI3Ks - Ph+ and Ph− B-ALL Badura et al. (2013);
Bashash et al. (2016)
ZSTK-474 Class IA PI3Ks Dexamethasone, Imatinib,
Nilotinib, GZD824
Ph+ and Ph− B-ALL Evangelisti et al. (2018);
Ultimo et al. (2017)
BYL719 p110α PI3K Imatinib, Nilotinib, GZD824 Ph+ and Ph-like B-ALL Tasian et al. (2017);
Ultimo et al. (2017)
CAL-101 p110δ PI3K Doxorubicin, Vincristine Ph− and Ph-like B-ALL Adam et al. (2017);
Kruth et al. (2017);
Safaroghli-Azar et al. (2017);
Tasian et al. (2017)
IPI-145 p110γ/δ PI3K Dexamethasone, Imatinib,
Nilotinib, GZD824
Ph+ and Ph− B-ALL Evangelisti et al. (2017);
Ultimo et al. (2017)
GSK690693 Akt - Ph+ and Ph− B-ALL Levy et al. (2009)
MK2206 Akt RAD001 Ph− B-ALL Neri et al. (2014)
Rapamycin mTORC1 U0126, AG490, 3-BrOP,
Daunorubicin, Imatinib
Ph+, Ph− and Ph-like B-ALL Akers et al. (2011);
Bertrand et al. (2005);
Brown et al. (2003);
Hirase et al. (2009);
Maude et al. (2012);
Yang et al. (2012), (2014)
CCI-779 mTORC1 ABT-737 Ph- B-ALL Iacovelli et al. (2015);
Teachey et al. (2006)
RAD001 mTORC1 MK2206, Bortezomib,
Vincristine, Imatinib
Ph+, Ph− and Ph-like B-ALL Crazzolara et al. (2009);
Baraz et al. (2014);
Frolova et al. (2012);
Kuwatsuka et al. (2011);
Saunders et al. (2011), (2013)
PI-103 PI3K/mTOR Imatinib Ph+ B-ALL Kharas et al. (2008)
BEZ235 PI3K/mTOR Dexamethasone, Cytorabine,
Doxurubicin, Nilotinib, GX15-070
Ph+ and Ph− B-ALL Ding et al. (2013);
Schult et al. (2012);
Stefanzl et al. (2017);
Wong et al. (2014)
BGT226 PI3K/mTOR - Ph- B-ALL Wong et al. (2014)
PF05212384 PI3K/mTOR Ruxolitinib, Dasatinib Ph-like B-ALL Tasian et al. (2017)
PP242 mTORC1/mTORC2 Dasatinib Ph+ B-ALL Janes et al. (2010)
TAK-228 mTORC1/mTORC2 Dasatinib Ph+, Ph− and Ph-like B-ALL Janes et al. (2013);
Vo et al. (2017);
Yun et al. (2016)
AZD2014 mTORC1/mTORC2 - Ph-like B-ALL Tasian et al. (2017)
OSI-027 mTORC1/mTORC2 - Ph+ and Ph− B-ALL Yun et al. (2016)
Torin-2 mTORC1/mTORC2 - Ph− B-ALL Simioni et al. (2014)
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translocation of the GC receptor and counteracted stromal cell-
induced DEX-resistance (Evangelisti et al., 2018). Moreover, we
performed gene expression analysis which demonstrated that the
combination consisting of ZSTK-474 and DEX strengthened the DEX-
induced up- or downregulation of several genes involved in apoptosis,
however the combination also rescued the effects of genes that might
be involved in GC-resistance. Another group has recently demon-
strated that CAL-101 synergizes with DEX in Ph- B-ALL cell lines and
primary samples from DEX-resistant patients (Kruth et al., 2017).
It has been proposed that PI3K/Akt/mTOR signaling is involved in
the resistance of Ph+ B-ALL cells to the TKI, imatinib (Guo et al., 2017;
Xing et al., 2012; Wang et al., 2014). For this reason, our group has
recently investigated the therapeutic potential of combining PI3K
inhibitors with TKIs in the Ph+ B-ALL cell line SUP-B15. We used the
pan p110 PI3K inhibitor ZSTK-474, the p110α PI3K inhibitor BYL719
and the dual γ/δ p110 PI3K inhibitor IPI-145. As to TKIs, we employed
imatinib, the second generation Bcr-Abl inhibitor nilotinib and the third
generation orally bioavailable TKI, GZD824 (Ultimo et al., 2017). Of
note, GZD824 is effective against a wide range of Bcr-Abl mutants,
including T315I (Ren et al., 2013). We observed synergistic cytotoxic
effects with the various combinations which were due to apoptosis
induction. However, the combined treatments also induced
autophagy, which might have a protective effect (Ultimo et al.,
2017). In this connection, it is important to emphasize how an ATP-
competitive dual inhibitor of PI3K p110δ/Vps34, PI3KD/V-IN-01,
exhibited better antiproliferative activity against cell lines representa-
tive of B-cell malignancies than known selective PI3K p110δ and
Vps34 inhibitors (Liu et al., 2016). PI3KD/V-IN-01 has not been tested
in B-ALL preclinical settings, however, its use should be considered in
light of our own findings (Ultimo et al., 2017).
Overall, all of the above highlighted results support the rationale
for clinical testing of either pan p110 or isoform-selective PI3K
inhibitors in B-ALL patients, especially in combination with traditional
chemotherapeutic drugs or TKIs, and provide useful insights needed to
optimize the therapeutic strategy, including the protective role played
by autophagy when leukemic cells are treated with PI3K inhibitors.
5.1 | Akt inhibitors
Historically, Akt has been a difficult target to inhibit with ATP-
competitive small molecules. Indeed, the ATP-binding pocket of Akt
sharesmany homologies with other members of the AGC kinase family
(Pearce, Komander, & Alessi, 2010). GSK690693 is an ATP-competi-
tive inhibitor which targets Akt (Rhodes et al., 2008). GSK690693 has
FIGURE 2 Small molecule inhibitors used for targeting the key nodes of the PI3K/Akt/mTOR cascade in preclinical models of B-ALL. For
the details, see the text
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been tested in Ph+ and Ph− B-ALL cell lines where it induced a cell
proliferation block and apoptosis accompanied by a dephosphoryla-
tion of Akt downstream targets, including GSK3β, PRAS40, and
p70S6K (Levy, Kahana, & Kumar, 2009). Importantly, both stimulated
peripheral blood CD4+ T-cells from healthy donors and mouse
thymocytes were less sensitive to GSK690693 than leukemic cells.
Nevertheless, dose-limiting toxicities that are likely on target,
associated with hyperglycemia, led to termination of the clinical
development of this drug (Manning & Toker, 2017). MK2206 is a
specific, potent, and orally bioavailable allosteric inhibitor that targets
both the catalytic and the PH domains of Akt (Hirai et al., 2010). We
have shown that MK2206 strongly synergized with the mTORC1
inhibitor, RAD001, in both Ph− B-ALL cell lines and patient samples
(Neri et al., 2014). Our findings could have important implications, as
MK2206 has not shown significant efficacy in the clinic as single agent
therapy in patients with acute myelogenous leukemia (Konopleva
et al., 2014). However, its effects could be conceivably enhanced by
other drugs used in combination therapy.
5.2 | Allosteric mTOR inhibitors
Allosteric mTOR inhibitors (rapamycin, CCI-779, RAD001) have been
widely used in preclinical models of B-ALL. For example, rapamycin
negatively affected in vitro the growth of Eµ-ret transgenic mouse-
derived cell lines as well as that of Ph− human B-ALL cell lines (NALM-
6, NALM-16). Moreover, rapamycin induced apoptosis in the murine
pro-B ALL cell line T309 (Brown et al., 2003). Interestingly, the
inhibitory effects of rapamycin could be reversed by IL-7, which
suggests an important role of this cytokine in the control of mTOR
activity in B-ALL cells. Rapamycin was also effective in vivo, as it
extended survival in Eµ-ret transgenic mice with advanced B-ALL
compared with control littermates (Brown et al., 2003).
In vitro, CCI-779 (Temsirolimus) dramatically decreased survival
and increased apoptosis of lymphoblasts fromPh- B-ALL adult patients
co-cultured with bone marrow stromal cells. The drug was also
effective in vivo in a NOD/SCID xenograft model (Teachey et al.,
2006). Recently, CCI-779 has been shown to synergize with the Bcl-2
inhibitor, ABT-737, in ABT-737-resistant pediatric and adult Ph− B-
ALL cells, by downregulating mTORC1 activity and Mcl-1 (Iacovelli
et al., 2015).
Also RAD001 has proven its efficacy, especially in models of Ph−
pediatric B-ALL. Importantly, RAD001 synergized with conventional
chemotherapy (e.g., vincristine) or novel agents (e.g., bortezomib) both
in vitro and in vivo, with increased caspase-dependent, but p53-
independent, cell killing (Saunders, Cisterne, Weiss, Bradstock, &
Bendall, 2011; Saunders et al., 2013). However, it has also been shown
that RAD001 induces other types of cell death, including autophagy
(Crazzolara, Bradstock, & Bendall, 2009) and caspase-independent
paraptosis (Baraz et al., 2014).
It should be considered that interactions between leukemic cells
and the bone marrow microenvironment promote B-ALL cell survival
and confer resistance to chemotherapy (Chiarini et al., 2016). Hypoxia
is an integral component of bone marrow microenvironment (Petit
et al., 2016). Hypoxia-inducible factor-1α (HIF-1α) plays key roles in
response to hypoxia by regulating leukemic cell growth and metabolic
adaptation to hypoxia, as well as drug-resistance (Deynoux, Sunter,
Herault, & Mazurier, 2016). Remarkably, mTOR blockade with
RAD001 reduced HIF-1α expression, diminished glucose uptake and
glycolytic rate, and partially restored the chemosensitivity of B-ALL
cells co-cultured with bone marrow stromal cells under hypoxic
conditions (Frolova et al., 2012).
In this connection it is important to emphasize that cancer cells,
including acute leukemia cells, show the propensity to metabolize
glucose to lactate for ATP production even under aerobic conditions,
the so-called “Warburg effect” (Kalyanaraman, 2017). Therefore, drugs
targeting glycolysis are now being studied for developing innovative
anticancer therapies (Granja, Pinheiro, Reis, Martinho, & Baltazar,
2015). mTORC1 senses metabolic stresses, such as lowered glucose
metabolite levels, and ATP concentrations, and compensates for these
stresses, allowing cells to become resistant to glycolysis inhibition
(Jellusova & Rickert, 2016). Interestingly, rapamycin potentiated the
effects of the novel, third-generation glycolysis inhibitor, 3-bromo-2-
oxopropionate-1-propyl ester (3-BrOP), a cell permeable ester of 3-
bromopyruvate (3-BrPA) (Lis et al., 2016). NALM-6 B-ALL cells treated
with 3-BrOP and rapamycin displayed a decrease in viability compared
to either agent alone (Akers et al., 2011). These findings suggest that
when ATP is depleted by glycolysis inhibition, simultaneous targeting
of mTORC1 may further limit nutrient uptake, ensuing in stronger
cytotoxic effects.
Rapamycin has shown efficacy in preclinical models of xeno-
grafted pediatric Ph-like B-ALL with and without CRLF2 and JAK
genetic lesions. Indeed, the drug controlled leukemia burden in all eight
B-ALL samples analyzed, while a prolonged survival was observed in
two representative xenografts treated with rapamycin when com-
pared with vehicle (Maude et al., 2012).
As to Ph+ B-ALL, it has been shown that rapamycin was cytotoxic
not only for the Bcr-Abl+ leukemic lymphoid cell line, SU-Ph2, but also
for the imatinib-resistant cell line, SU/SR, that has acquired the T315I
mutation (Hirase, Maeda, Takai, & Kanamaru, 2009). Moreover,
rapamycin potentiated the effects of imatinib in SUP-B15 Ph+ B-
ALL cells and primary samples from patients when combined with
daunorubicin (Yang et al., 2012). Remarkably, it was reported that
daunorubicin treatment up-regulated mTORC1 signaling, whereas
rapamycin effectively counteracted such a deleterious side effect,
which might dampen daunorubicin ability to kill leukemic cells. The
same group subsequently reported that imatinib enhanced mTORC1
signaling, therefore its association with rapamycin increased imatinib
cytotoxicity in SUP-B15 cells (Yang et al., 2014).
Importantly, it has also been shown that RAD001 overcame
resistance to imatinib by targeting in vitro and in vivo a mostly
quiescent Ph+ B-ALL cell subset (CD34+/CD38-) (Kuwatsuka et al.,
2011). It is well known that this cell subset is enriched in leukemic stem
cells (LSCs) that are intrinsically resistant to TKIs, probably, although
not exclusively, due to their quiescence (Graham et al., 2002).
The RAD001/imatinib combined treatment induced in vitro
apoptosis of CD34+/CD38− cells more efficiently than RAD001 alone
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(Kuwatsuka et al., 2011). These findings imply that co-treatment with
RAD001 can overcome resistance to imatinib in Ph+ B-ALL LSCs and
may pave the way for more effective treatments aimed to lower the
percentage of patients who relapse after TKI treatment.
Together, all these preclinical observations suggest that allosteric
mTOR inhibitors, especially when combined with conventional
chemotherapy or novel targeted agents, have the potential to improve
clinical responses in patients with different types of B-ALL, including
high risk Ph+ and Ph-like cases.
5.3 | Dual PI3K/mTOR inhibitors
Since both PI3K and mTOR belong to the PIKK superfamily of kinases,
they share high sequence homology in their catalytic domains. Dual
PI3K/mTOR inhibitors were originally developed as PI3K inhibitors,
but were subsequently shown to also effectively inhibit both mTORC1
and mTORC2 (Chiarini, Evangelisti, McCubrey, & Martelli, 2015). The
use of this class of drugs should blunt mTORC2-dependent activation
of Akt effected through PI3K (Janes et al., 2010).
PI-103, BEZ235, BTG226, and PF05212384 (Gedatolisib) are dual
PI3K/mTOR inhibitors that have been employed in preclinical models
of B-ALL.
PI-103 was more efficacious than rapamycin at suppressing
proliferation of murine and human Ph+ B-ALL leukemia cells treated
with the TKI inhibitor, imatinib (Kharas et al., 2008). BEZ235 displayed
cytotoxic effects in both Ph− (Schult et al., 2012; Wong, Welschinger,
Hewson, Bradstock, & Bendall, 2014) and Ph+ B-ALL cells (Ding et al.,
2013), while BTG226 has been tested only in Ph−models, where it was
more powerful than BEZ235 (Wong et al., 2014). Both drugs, however,
inhibited the proliferation of Ph- B-ALL cell lines with a three log
greater potency than RAD001 (Wong et al., 2014). BEZ235 synergized
with traditional chemotherapeutic drugs, including cytarabine, doxo-
rubicin, and DEX in Ph− B-ALL cells (Schult et al., 2012), while the
inhibitor was synergistic with the second-generation TKI, nilotinib, in
Ph+ SUP-B15 cells. Interestingly, nilotinib, when administered alone,
upregulated PI3K/Akt/mTOR signaling (Ding et al., 2013). Moreover,
BEZ235 has been recently shown to synergize with the Bcl-2 inhibitor,
GX15-070 (Obatoclax@), in Ph+ and Ph− primary B-ALL cells and cell
lines (Stefanzl et al., 2017).
While the clinical development of BEZ235 and BTG226 has been
halted, that of PF05212384 is being continued (Rodon & Tabernero,
2017). Remarkably, PF05212384 displayed anticancer activity in
childhood B-ALL patient-derived xenograft models harboring various
Ph-like genomic alterations (Tasian et al., 2017). PF05212384 was
particularly effective in CRLF2/JAK-mutant models with a mean
92.2% leukemia proliferation reduction versus vehicle controls and
significantly prolonged mice survival. It displayed a lower efficacy in
Abl/PDGFR-mutant models. Overall, PF05212384 was more potent
than the p110α PI3K inhibitor BYL719, the p110δ PI3K inhibitor
CAL-101, or the mTORC1/mTORC2 inhibitor AZD2014. Neverthe-
less, the efficacy of PF05212384 monotehrapy was enhanced by
combining the PI3K/mTOR inhibitor with either a JAK inhibitor
(Ruxolitinib) in CRLF2/JAK-mutant models or the TKI dasatinib in
Abl/PDGFR-mutant models (Tasian et al., 2017). These data
suggested that Ph-like B-ALL requires PI3K/Akt/mTOR pathway
activation for survival in vivo. Moreover, they indicated that clinical
trials testing combinations of kinase inhibitors in Ph-like B-ALL
patients are warranted.
6 | ATP-COMPETITIVE mTORC1/mTORC2
INHIBITORS
This class of drugs, that target both mTOR complexes but not PI3K,
was designed to reduce toxicity due to the use of dual PI3K/mTOR
inhibitors (Pal & Quinn, 2013). Moreover, these inhibitors can
potentially prevent the feedback loop activation of Akt caused by
rapamycin/rapalogs in B-ALL cells (Badura et al., 2013). In analogywith
dual PI3K/mTOR inhibitors, the ATP-competitive mTORC1/mTORC2
inhibitor PP242, displayedmore powerful cytotoxic effects as well as a
more complete inhibition of mTORC1 outputs compared with
rapamycin in preclinical models of murine and human Ph+ B-ALL cells
(Janes et al., 2010).
TAK-228 (formerly known as INK128/MLN0128) is an orally
active mTORC1/mTORC2 inhibitor currently in clinical development.
TAK-228 suppressed proliferation of B-ALL cell lines in vitro and
reduced colony formation by primary human leukemia cells from both
adult and pediatric Ph− B-ALL patients. TAK-228 also increased the
efficacy of dasatinib in Ph+ primary samples (Janes et al., 2013). This
inhibitor was also effective in various in vivo models of B-ALL,
including a syngeneicmicemodel of lymphoid Ph+ disease, and primary
xenografts of either Ph+ or Ph− human B-ALL samples, Remarkably, in
all the in vivomodels, TAK-228waswell tolerated and did not suppress
endogenous bone marrow proliferation (Janes et al., 2013). Very
recently, however, it has been shown that inhibiting mTORC1 with
TAK-228 protected Ph+ and Ph-like B-ALL cells from killing by
methotrexate and 6-mercaptopurine, two drugs used in maintenance
chemotherapy. These cytoprotective effects of TAK-228 correlated
with decreased cell-cycle progression and were also detected with
cell-cycle inhibitors, such as palbociclib or aphidicolin (Vo et al., 2017).
Using xenograft models, it was observed thatmTOR inhibition by TAK-
228 actually increased the number of leukemia cells that emerged after
cessation of chemotherapy treatment.
Interestingly, the use of TAK-228 and shRNA-mediated down-
regulation of either Raptor or Rictor allowed the identification of two
previoulsy unrecognized mTOR-dependent pathways critical for Ph+
and Ph− B-ALL cell survival. Inhibition of mTORC1-mediated 4E-BP1
phosphorylation led to decreased expression of c-Myc and subsequent
upregulation of the proapoptotic Bcl-2 family member PUMA,
whereas inhibition of mTORC2 resulted in NF-κB-mediated expres-
sion of the Early Growth Response 1 (EGR1) gene, that encodes a
transcription factor which binds and transactivates the proapoptotic
BCL2L11 gene encoding Bim protein (Yun et al., 2016). Importantly, 1
or both pathways contributed to apoptosis of malignant B-ALL cells
after treatment with the dual mTORC1/mTORC2 inhibitors, OSI-027
and TAK-228.
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Our group has documented that the ATP-competitive mTORC1/
mTORC2 inhibitor, Torin-2, was cytotoxic to a panel of Ph− B-ALL cell
lines and indeed suppressed the rapalog-dependent feedback activa-
tion of Akt, whereas RAD001 required the addition of the Akt inhibitor
MK-2206 to achieve the same effects (Simioni et al., 2014).
Overall, these findings support the rationale for clinical testing of
ATP-competitivemTORC1/mTORC2 inhibitors in both Ph+ and Ph− B-
ALL patients. However, they also highlight that inhibitors targeting
mTOR should be used with caution in combination with chemothera-
peutic drugs that rely on cell-cycle progression to kill leukemic cells.
7 | CONCLUSIONS AND FUTURE
DIRECTIONS
The evidence reviewed here documents that PI3K/Akt/mTOR-
generated signals play central roles in the control of B-ALL cell
proliferation, survival, metabolism, and drug-resistance, making this
signal transduction cascade an attractive target for antileukemic
therapy. These findings have highlighted PI3K/Akt/mTOR inhibitors as
molecules to be possibly tested in clinical trials aimed to treat B-ALL
patients, although several fundamental outstanding issues still need to
be addressed.
In particular, will inhibition of PI3K/Akt/mTOR signaling nega-
tively affect leukemic cells without deleterious side effects on healthy
cells? In other words, is there a therapeutic window when such a
ubiquitous signal transduction cascade is to be targeted? While the
discovery of PI3K/Akt/mTOR inhibitors yielded a flood of promising
and exciting preclinical data, the initial wave of clinical trials based on
these drugs has not resulted in widespread and durable patient
responses. These trials have demonstrated that PI3K/Akt/mTOR
pathway inhibitors frquently displayed significant on- and off-target
toxicities that were dose-limiting, often leading to the use of
subtherapeutic maximum tolerated doses, which resulted in insuffi-
cient pathway inhibition. Rapamycin/rapalogs were generally quite
well tolerated, however they have shown a modest anticancer activity
when used alone. This low efficacy is usually explained by the feedback
activation of Akt, as we have discussed in this review.
As a consequence of these trials, only a handful of these inhibitors
have been approved for clinical use as anticancer agents in theU.S. and
Europe (Chiarini et al., 2015; Rodon&Tabernero, 2017). The depth and
duration of target inhibition as well as safety profiles of these
compounds may be improved through the use of intermittent dosing
schedules, which could lead to a better drug exposure with more
effective target inhibition and fewer off-target adverse effects, as seen
in other types of cancer (Guichard et al., 2015; Tolcher et al., 2015;
Yates, Dudley, Cheng, D'Cruz, & Davies, 2015).
Furthermore, preclinical data strongly suggest that identifying
combinations, either with targeted agents or with chemotherapy,
might be the key to unleashing the full potential of PI3K/Akt/mTOR
inhibitors in B-ALL patients, aswe have highlighted in this review. Early
clinical data support this claim in other cancer types (Andre et al., 2014;
Moscetti et al., 2016), although it will have to be conclusively
demonstrated that improved clinical responses will not be accompa-
nied by unacceptable toxicities (Baselga et al., 2017).
Another critical issue will be the identification of biomarkers that
could accurately predict PI3K/Akt/mTORpathway inhibitor efficacy in
B-ALL patients. In this connection, techniques such as kinase activity
profiling and computational analysis could give a deeper insight in
active signal transduction pathways and point out critical signaling
hubs as well as new potential druggable targets or resistant patients, as
recently demonstrated also in B-ALL cells (Casado et al., 2013; van der
Sligte et al., 2015).
We also need to better understand the effects of the pathway
inhibitors on the immunosuppressive leukemic microenvironment.
Indeed, recent evidence pointed out that B-ALL cells induced inhibition
of T-cell Akt/mTORC1 signaling and glucose metabolism that drove T-
cell function impairment, while an enforced Akt/mTORC1 signaling
rescued T-cell metabolism and partially improved anti-leukemia
immunity (Siska et al., 2016). Therefore, the use of PI3K/Akt/mTOR
inhibitors could further blunt immunological responses against
leukemic cells.
In conclusion, the field of PI3K/Akt/mTOR targeted therapies has
progressed very rapidly over the past 15 years and, as our knowledge
of the biology continuously increases, so too will our capacity to
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